The peptide Epitalon (Epithalon; AEDG, Ala-Glu-Asp-Gly) has been administered in published animal studies and laboratory experiments at very different times, with varying frequencies, and for different durations. However, no controlled human studies have established the best time of day, the advantage of morning versus evening administration, or a standardized clinical cycle. [1–8]
Questions such as „when to use Epitalon,” „Epitalon in the morning or evening,” and „how long should an Epitalon cycle last?” are often discussed on the internet as if a single standard protocol existed. Published scientific literature does not support such a simplification.
Some studies used five consecutive days of administration each month, in others Epitalon was administered five times a week for many months, and still others involved short-term nasal exposure in rats. Oral administration studies sometimes lasted a month. Circadian rhythm studies measured nocturnal melatonin levels or evening hormonal responses, but the timing of measurements should not be equated with evidence that Epitalon itself should be administered in the evening.
When was Epitalon administered in studies?
Epitalon has been administered according to many different research regimens rather than at a single standard time. Animal studies have included, among others, five consecutive days of administration each month, five administrations per week for many months, single acute intranasal exposures, and monthly oral regimens. The schedule was chosen based on the studied endpoint rather than an validated human treatment protocol. [1–6]
One of the most transparent examples comes from a long-term aging study in mice. Female SHR mice of Swiss origin received 1 μg of Epitalon subcutaneously for five consecutive days each month, starting from the third month of life until natural death. [1]
In another study on female CBA mice, a similar monthly regimen was used, but with a lower experimental dose: 0.1 μg per animal for five consecutive days each month, starting from the sixth month of life until natural death. [2]
Other studies did not use monthly cycles. In one long-term mouse carcinogenesis study, Epitalon was administered by injection five times a week for 6.5 months. [3]
In turn, in a study on rats, Epithalon was administered orally for one month, analyzing the activity of small intestine enzymes. [4]
In the neurophysiological study on rats, acute intranasal administration was used, after which cortical neuronal activity was recorded shortly afterward, instead of conducting a long-term administration cycle. [5]
These examples show that the timing and administration schedule of Epitalon depended on the specific scientific question.
Epitalon in the morning or in the evening?
Published studies have not shown that Epitalon should be administered specifically in the morning or evening. Although several studies measured evening or nighttime melatonin levels due to Epitalon's association with pineal gland function and circadian rhythm, taking measurements during the biological night does not provide evidence of the superiority of evening administration. [6–8]
The question regarding morning or evening use stems largely from research on melatonin.
Melatonin is naturally subject to the circadian rhythm, with its concentration increasing during the biological night. Therefore, researchers analyzing the potential impact of Epitalon on age-related changes in pineal gland function often measured melatonin in the evening or at night.
For example, in a primate study, Epitalon significantly stimulated evening melatonin synthesis in aging rhesus macaques and was associated with the normalization of the circadian cortisol rhythm. [6]
Another study on rhesus macaques found lower nocturnal melatonin levels in older animals and analyzed whether Epitalon could affect age-related hormonal disorders. [7]
A separate publication involving old monkeys and elderly humans described the restoration of nocturnal levels of endogenous melatonin and the normalization of its circadian rhythm following the administration of pineal peptides. [8]
However, none of these results establish a clinical rule stating that Epitalon should be administered before sleep.
They show above all that the night is an important measurement period in the study of hormones related to the circadian rhythm.
According to published research, what is the best time of day?
The best time of day to use Epitalon has not been established. There is no controlled human study in the published literature directly comparing morning and evening administration and demonstrating superior efficacy, absorption, safety, impact on sleep, melatonin response, or longevity-related effects at either of those times.
An evidence-based answer to the question „what is the best time to take Epitalon?” would require a study directly comparing administration at different times of the day.
For example, researchers could compare morning versus evening administration while maintaining the same dose, route of administration, duration, study population, and experimental conditions. Pharmacokinetics, melatonin, circadian phase, sleep, adverse events, or another predefined endpoint could then be evaluated.
The available literature on Epitalon does not contain such a study.
This distinction is important because chronobiology can make the time of administration biologically relevant without indicating specifically which time is appropriate.
Melatonin itself is strongly time-dependent. In other experimental contexts, the biological response to melatonin can vary depending on the phase of the circadian rhythm. However, this general principle of chronobiology does not mean that Epitalon has the same administration-time-dependent profile.
Therefore, recommending the use of Epitalon in the morning or evening solely based on research regarding melatonin would go beyond the available evidence.
How long did Epitalon cycles last in studies?
Epitalon research cycles have ranged from a single acute exposure, through repeated five-day monthly cycles and monthly oral administration studies, to multi-month repeated administration and regimens covering a significant portion of the animal's lifespan. There is no single published cycle length that has been validated as an optimal regimen for humans. [1–5]
The duration largely depended on what the researchers intended to measure.
Five-day menstrual cycles
In a few classic studies on aging and cancer, five consecutive days of administration were used each month.
In a longevity experiment with SHR mice, a five-day monthly cycle was initiated at three months of age and continued until natural death. [1]
In a study on CBA mice, the same five-day monthly schedule was used, starting at six months of age. [2]
In the experiment on HER-2/neu transgenic mice, Epithalon was also administered for five consecutive days each month, starting from the second month of life. [9]
Five times a week for many months
Other studies used a more continuous design.
In one long-term experiment on C3H/He mice, Epitalon was administered five times a week for 6.5 months. [3]
Monthly oral administration
Old Wistar rats received Epithalon orally for one month in an intestinal enzyme study. [4]
Acute nasal examination
Neurophysiological studies with intranasal administration had a completely different design. Epitalon was administered once to anesthetized rats, and then cortical neuronal activity was recorded within a short experimental window. [5]
Therefore, the term „Epitalon cycle” describes many different historical protocols rather than a single evidence-based clinical standard.
How often was Epitalon administered?
In published research, Epitalon has been used at frequencies ranging from a single experimental exposure, to daily administration during short cycles, to five administrations per week and five consecutive days of administration repeated monthly. The frequency varied depending on the species and the endpoint, and no human dosing frequency has been established as clinically optimal. [1–5,9]
Frequency and duration should be considered separately.
The study may use a short but repeated cycle, for example, five consecutive days of administration each month.
Others may include frequent and prolonged exposure, for example five applications a week for several months.
In the study on SHR mice, five consecutive daily injections were administered each month. [1]
In the HER-2/neu study, five consecutive days of administration per month were also used. [9]
In the study on C3H/He mice, five injections per week were administered for 6.5 months. [3]
Meanwhile, in an acute nasal study in rats, a single administration was analyzed, following which neuronal activity was immediately recorded. [5]
These schemes cannot be compared solely by the number of doses. A five-day monthly aging protocol and a one-time intranasal electrophysiological experiment address completely different biological questions.
When were the effects of Epitalon measured in studies?
The effects of Epitalon have been measured across very different time frames—from minutes after nasal administration, through nocturnal hormone measurements and monthly biochemical endpoints, to multi-month cancer outcomes and lifelong survival. Therefore, there is no single evidence-based „onset of action” that would allow one to predict when a given person will feel an effect. [1,3–8]
The significance of the time of onset depends entirely on the endpoint being evaluated.
Minuty
In an in vitro study of the rat neocortex, researchers recorded spontaneous activity of cortical neurons following acute exposure and observed changes over subsequent minutes. [5]
It was an electrophysiological endpoint, not a clinical symptom or a therapeutic effect.
Evening or night
In older rhesus macaques, researchers measured evening or nighttime melatonin concentrations because this hormone is subject to a circadian rhythm. One study described significant stimulation of evening melatonin levels in aging monkeys. [6]
Studies involving humans and monkeys have also evaluated nocturnal melatonin in the context of age-related circadian rhythm disorders. [8]
One month
In the experiment on intestinal enzymes in rats, the results were evaluated after a month of oral administration. [4]
A few months
The tumor study in C3H/He mice lasted 6.5 months, and tumor development and toxicity were evaluated during this period. [3]
All my life
Some aging studies initiated administration relatively early and continued it until the natural death of the animals, which is why lifespan and the development of spontaneous tumors were the final endpoints. [1,2]
These differences mean that the statement „Epitalon works after X days” is not supported in the literature.
Does the duration of use differ depending on the route of administration?
Yes, the timing and study design differed depending on the route of administration, but this was due to the design of the experiments rather than evidence indicating that each route requires a specific time of day in humans. Intranasal studies often analyzed rapid neuronal responses, oral studies evaluated longer-term effects on the gastrointestinal tract, while injection studies frequently involved repeated protocols regarding aging or cancer, lasting weeks, months, or the entire lifespan of the animals.
Nasal
Epitalon administered nasally has been studied primarily in rats.
In a 2007 neocortex experiment, intranasal administration was used specifically to analyze rapid changes in neuronal activity. [5]
The short measurement time was therefore appropriate for this specific scientific question.
However, this does not establish when nasal Epitalon should be used by humans.
Orally
Oral administration studies have typically focused on slower-developing biological effects.
In the intestinal study on old Wistar rats, Epithalon was administered orally for one month before the evaluation of enzyme activity. [4]
There are no robust pharmacokinetic data in humans showing whether morning, evening, fasting, or postprandial administration significantly alters exposure to oral Epitalon.
Injections
Subcutaneous administration dominates in classical gerontology and carcinogenesis literature.
These studies have often used repeated cycles lasting many months or until natural death, rather than focusing on immediate effects dependent on the time of day. [1–3,9]
Historical injection protocols therefore provide information primarily on frequency and duration, but typically do not indicate the preferred time of administration within the circadian rhythm.
How to interpret the evidence regarding the timing of Epitalon use?
Research indicates a clear difference between the administration time, the measurement time, and the cycle structure.
| Question about time | What do the published proofs confirm |
|---|---|
| Has it been proven that it is best to use it in the morning? | Not |
| Has it been proven that it is best to use it in the evening? | Not |
| Were night effect measurements performed? | Yes, especially melatonin [6–8] |
| Have five-day cycles been studied? | Yes, in several mouse models [1,2,9] |
| Was Epitalon administered five times a week? | Yes, in some long-term animal studies [3] |
| Have monthly oral regimens been studied? | Yes, in rats [4] |
| Have the acute effects of intranasal administration been studied? | Yes, in rats [5] |
| Is there a validated cycle length for humans? | Not |
| Has the time of onset in humans been determined? | Not |
| Does nighttime measurement of melatonin prove that evening administration is best? | Not |
So the most important conclusion is:
Published Epitalon studies describe many different research protocols, but do not specify a single clinically validated time of day, cycle length, frequency, or onset of action in humans.
Frequently asked questions about the duration of Epitalon use
Should Epitalon be used in the morning or in the evening?
There are no controlled human studies demonstrating the superiority of morning or evening administration. In Epitalon studies, nocturnal melatonin levels were often measured because this hormone naturally follows a circadian rhythm, but the nighttime timing of the measurement does not prove that Epitalon itself should be administered in the evening.
Is Epitalon better in the evening because of melatonin?
This has not been demonstrated. Studies on primates and limited older studies in humans have described changes in evening or nighttime melatonin levels, but no study has directly compared morning and evening administration of Epitalon, demonstrating a better effect of evening use on melatonin, sleep, safety, or longevity. [6–8]
How long does an Epitalon treatment cycle last?
There is no single standard cycle. Published animal studies have included five consecutive days of repeated monthly dosing, schedules of five doses per week for multiple months, monthly oral exposure, and long-term administration until natural death. [1–4,9]
How often was Epitalon administered in the studies?
The frequency ranged from a single acute intranasal administration to five consecutive days of administration each month or five administrations per week. The regimen depended on the species and the study endpoint, rather than a standardized clinical protocol. [1–5]
How fast does Epitalon work?
A validated time to onset of action in humans has not been established. Laboratory results were measured within minutes of intranasal exposure, during evening or nighttime hormone measurements, after a month of oral administration, after several months, or throughout the animal's lifetime. These research observation periods should not be interpreted as the time to treatment effect in humans.
Does nasal Epitalon work faster than injected or oral Epitalon?
In a study on rats, neuronal effects were detected within minutes after intranasal administration, but this does not prove that intranasal Epitalon works clinically faster or more effectively in humans. Different routes of administration have not been compared in controlled pharmacokinetic or efficacy studies involving humans. [5]
Limitations of evidence regarding duration of use and cycles
The biggest limitation is that most of the data on duration of use come from animal studies, rather than from controlled pharmacological studies in humans.
Another limitation is the fact that individual studies were designed for different endpoints. Acute neuronal activity, nocturnal melatonin, intestinal enzyme activity, tumor development, and lifespan require completely different designs.
Thirdly, the literature essentially contains no direct comparisons of morning and evening administration.
Fourth, the timing of outcome measurement is easily confused with the time of administration. Measuring melatonin at night does not necessarily mean the peptide was administered in the evening, and even if it was, such a design alone does not prove the superiority of this timing.
Fifthly, there is a lack of robust human pharmacokinetic data. Without validated information on absorption, distribution, metabolism, elimination, and changes in exposure over time, there is no strong basis for determining the optimal chronotherapeutic administration window.
Finally, the regimens repeating in older studies, such as five consecutive days per month, should be treated as protocols of specific studies rather than universally validated „cycles”.
Disclaimer
This material is intended solely for educational and scientific-informational purposes. It does not constitute medical advice, dosage instructions, treatment recommendations, or recommendations for the use of Epitalon. Epitalon/Epithalon (AEDG; Ala-Glu-Asp-Gly) is not an FDA- or EMA-approved treatment for anti-aging, sleep disorders, circadian rhythm disorders, telomere modification, or longevity. No clinically validated dosing regimen has been established for human use that specifies whether to take it in the morning or evening, the duration of treatment, the length of the treatment cycle, or the frequency of dosing for these applications. The experimental regimens described above are derived primarily from animal studies and should not be adapted into self-administered protocols. Individuals considering experimental peptides should consult a qualified healthcare professional and verify current regulatory information with the appropriate authorities.
References
[1] Anisimov, V. N., Khavinson, V. K., Popovich, I. G., Zabezhinski, M. A., Alimova, I. N., Rosenfeld, S. V., Zavarzina, N. Y., Semenchenko, A. V., & Yashin, A. I. (2003). Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology, 4(4), 193–202. https://doi.org/10.1023/A:1025114230714
[2] Anisimov, V. N., Khavinson, V. K., Mikhalski, A. I., & Yashin, A. I. (2001). Effect of synthetic thymic and pineal peptides on biomarkers of ageing, survival and spontaneous tumour incidence in female CBA mice. Mechanisms of Ageing and Development, 122(1), 41–68. https://doi.org/10.1016/S0047-6374(00)00184-6
[3] Kossoy, G., Anisimov, V. N., Ben-Hur, H., Kossoy, N., & Zusman, I. (2006). Effect of the synthetic pineal peptide Epitalon on spontaneous carcinogenesis in female C3H/He mice. In Vivo, 20(2), 253–257. https://pubmed.ncbi.nlm.nih.gov/16634527/
[4] Khavinson, V. K., Timofeeva, N. M., Malinin, V. V., Gordova, L. A., & Nikitina, A. A. (2002). Effect of Vilon and Epithalon on activity of enzymes in epithelial and subepithelial layers in small intestine of old rats. Bulletin of Experimental Biology and Medicine, 134(6), 562–564. https://pubmed.ncbi.nlm.nih.gov/12660839/
[5] Sibarov, D. A., Vol’nova, A. B., Frolov, D. S., & Nozdrachev, A. D. (2007). Effects of intranasal administration of Epitalon on neuron activity in the rat neocortex. Neuroscience and Behavioral Physiology, 37(9), 889–893. https://doi.org/10.1007/s11055-007-0095-3
[6] Khavinson, V., Goncharova, N., & Lapin, B. (2001). Synthetic tetrapeptide Epitalon restores disturbed neuroendocrine regulation in senescent monkeys. Neuro Endocrinology Letters, 22(4), 251–254. https://pubmed.ncbi.nlm.nih.gov/11524632/
[7] Goncharova, N. D., Vengerin, A. A., Khavinson, V. K., & Lapin, B. A. (2005). Pineal peptides restore the age-related disturbances in hormonal functions of the pineal gland and the pancreas. Experimental Gerontology, 40(1–2), 51–57. https://doi.org/10.1016/j.exger.2004.10.004
[8] Korkushko, O. V., Lapin, B. A., Goncharova, N. D., Khavinson, V. K., Shatilo, V. B., Vengerin, A. A., Antoniuk-Shcheglova, I. A., & Magdich, L. V. (2007). Normalizing effect of pineal gland peptides on the daily melatonin rhythm in aged monkeys and elderly people. Advances in Gerontology, 20(1), 74–85. https://pubmed.ncbi.nlm.nih.gov/17969590/
[9] Anisimov, V. N., Khavinson, V. K., Alimova, I. N., Provinciali, M., Mancini, R., & Franceschi, C. (2002). Epithalon inhibits tumor growth and expression of HER-2/neu oncogene in breast tumors in transgenic mice characterized by accelerated aging. Bulletin of Experimental Biology and Medicine, 133(2), 167–170. https://doi.org/10.1023/A:1015555023692